Omeprazole
OMEPRAZOLE.
Omeprazole was one of the first proton pump inhibitors bought onto the market in the late 1980’s, they appear to be the drug of choice for most gastric related disorders (Der, 2003)
Omeprazole is the author’s drug of choice and it will be demonstrated through a drug framework. This drug has particular interest because of the gastroenterology nursing environment the author works in. Discussion based around the drug framework will include, structure, formulation, indications for use, pharmacodynamic effect, pharmacokinetic effects, contraindications, adverse reaction, interactions with other drugs and lastly monitoring, ethical and legal issues relating to Omeprazole.
Omeprazole is the generic name given to the drug, it is also commonly known as Losec (trade name). Omeprazole is used mainly for the treatment of gastro esophageal reflux disease (gord), duodenal and gastric ulcers, acid related dyspepsia which is more commonly know as heartburn (Biddle, 2003). The literature also states that Omeprazole is used in the treatment or eradication of H. pylori, a bacterium that can weaken the lining of the stomach and lead to ulceration.
The appearance of Omeprazole is an off white coloured crystalline powder which is freely soluble in ethanol, methanol and partially soluble in water. The active ingredient comes from a chemical class named benzimidazole and is broken down as: 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H- benzimidazole, this compound inhibits gastric secretion. The empirical formula of Omeprazole is C17H19N3O3S, it has a molecular weight of 345.42 and has a structural formula displayed below:
[pic](Rxlist.com, 2007)
In New Zealand Omeprazole is available in four formulations. Omeprazole oral suspension for use with nasogastric tubes and patients with swallowing difficulties. Omeprazole delayed release capsules with enteric coated granules, available in 10mg, 20mg, and 40mg doses. Omeprazole 40mg
Omeprazole was one of the first proton pump inhibitors bought onto the market in the late 1980’s, they appear to be the drug of choice for most gastric related disorders (Der, 2003)
Omeprazole is the author’s drug of choice and it will be demonstrated through a drug framework. This drug has particular interest because of the gastroenterology nursing environment the author works in. Discussion based around the drug framework will include, structure, formulation, indications for use, pharmacodynamic effect, pharmacokinetic effects, contraindications, adverse reaction, interactions with other drugs and lastly monitoring, ethical and legal issues relating to Omeprazole.
Omeprazole is the generic name given to the drug, it is also commonly known as Losec (trade name). Omeprazole is used mainly for the treatment of gastro esophageal reflux disease (gord), duodenal and gastric ulcers, acid related dyspepsia which is more commonly know as heartburn (Biddle, 2003). The literature also states that Omeprazole is used in the treatment or eradication of H. pylori, a bacterium that can weaken the lining of the stomach and lead to ulceration.
The appearance of Omeprazole is an off white coloured crystalline powder which is freely soluble in ethanol, methanol and partially soluble in water. The active ingredient comes from a chemical class named benzimidazole and is broken down as: 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H- benzimidazole, this compound inhibits gastric secretion. The empirical formula of Omeprazole is C17H19N3O3S, it has a molecular weight of 345.42 and has a structural formula displayed below:
[pic](Rxlist.com, 2007)
In New Zealand Omeprazole is available in four formulations. Omeprazole oral suspension for use with nasogastric tubes and patients with swallowing difficulties. Omeprazole delayed release capsules with enteric coated granules, available in 10mg, 20mg, and 40mg doses. Omeprazole 40mg
References: AstraZeneca (2006). LOSEC Intravenous. [Product data sheet]. New South Wales, Australia. AstraZeneca (2006). LOSEC: Omeprazole magnesium delayed released tablets. [Product monograph]. Ontario, Canada. Biddle, W., (2003) Gastrosphageal Reflux Disease: Current Treatment Approaches. Gastroenterology Nursing, 26(6) pg, 228 – 236. Bryant, B., Knights, K., Salerno, E. (2003) Pharmacology for health professionals. Australia: Mosby CMP Medica Der, G. (2003) An overview of Proton Pump Inhibitors. Gastroenterology Nursing, 26(5) pg 182-190. Faber, J., Azzugnuuni, S., DiRommana, M., Vanhaverbeek, N. (1990) Fatal confusion between Lasix and Losec, Lancet 6:338, p56-57. Kell, P. (2005). Phar4macodynamics [NURX 416 Nursing – applied pharmacology 2008 course notes]. Christchurch, New Zealand: University of Otago. Prilosec Side Effects & Drug Interactions. RxList.com (2007). Retrieved on 05.03.08 Taylor, M., Reide, P Up-To-Date. (2007). Omeprazole: Drug information. Lexi-Comp